7563 MCP/YpsA-related
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 3 | 5.3 | 0.56× | q = 0.30 | |
| Nucleosides, nucleotides, and analogues | 5 | 3.0 | 1.67× | not tested | |
| Organic oxygen compounds | 2 | 2.2 | 0.93× | not tested | |
| Homogeneous non-metal compounds | 2 | 2.3 | 0.86× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00131 | AMP | Adenosine phosphate | 11 |
| DB01694 | TAR | D-tartaric acid | 4 |
| DB02059 | AR6 | Adenosine-5-Diphosphoribose | 2 |
| DB00825 | — | — | 1 |
| DB01016 | — | Glyburide | 1 |
| DB01744 | — | Camphor | 1 |
| DB02580 | PG6 | Pentaglyme | 1 |
| DB04352 | RP5 | beta-D-Ribose-5-phosphate | 1 |
| DB09061 | — | Cannabidiol | 1 |
| DB11345 | — | — | 1 |
| DB11755 | — | Tetrahydrocannabivarin | 1 |
| DB14011 | — | — | 1 |
| DB14123 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 112 |
| CLR | CHOLESTEROL | 56 |
| APR | ADENOSINE-5-DIPHOSPHORIBOSE | 53 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 20 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 17 |
| KX7 | Icilin | 16 |
| OJC | (2R,3R,3aS,5S,6R,7S,8R,11R,13S,15aR)-2-(6-amino-9H-purin-9-yl)-3,6,7,11,13-pentahydroxyoctahydro-2H,5H,11H,13H-5,8-epoxy-11lambda~5~,13lambda~5~-furo[2,3-g][1,3,5,9,2,4]tetraoxadiphosphacyclotetradecine-11,13-dione | 14 |
| RK3 | (1S,3S,4R,5R,7R,15R,16S,17R)-5-imidazo[2,1-f]purin-3-yl-10,12-bis(oxidanyl)-10,12-bis(oxidanylidene)-2,6,9,11,13,18-hexaoxa-10$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{3,7}]octadecane-4,16,17-triol | 12 |
| ULO | nonyl(oxo)di(propan-2-yl)-lambda~5~-phosphane | 12 |
| AMP | ADENOSINE MONOPHOSPHATE | 11 |
| MGmetal | MAGNESIUM ION | 10 |
| 0O2 | guanosine 5'-(tetrahydrogen triphosphate) 3'-(trihydrogen diphosphate) | 8 |
| LQ7 | N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-[(thiophen-2-yl)methyl]benzamide | 8 |
| NAmetal | SODIUM ION | 7 |
| ZNmetal | ZINC ION | 7 |
| AR6 | [(2R,3S,4R,5R)-5-(6-AMINOPURIN-9-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHYL[HYDROXY-[[(2R,3S,4R,5S)-3,4,5-TRIHYDROXYOXOLAN-2-YL]METHOXY]PHOSPHORYL] HYDROGEN PHOSPHATE | 6 |
| CL | CHLORIDE ION | 6 |
| A2R | [(2R,3R,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3-HYDROXY-4-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL [(2R,3S,4R,5R)-3,4,5-TRIHYDROXYTETRAHYDROFURAN-2-YL]METHYL DIHYDROGEN DIPHOSPHATE | 5 |
| HSX | 5-O-phosphono-alpha-D-ribofuranose | 5 |
| 9PE | (1R)-2-{[(S)-(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-1-[(heptanoyloxy)methyl]ethyl octadecanoate | 4 |